Uniqure Plummets 40% On Another Shocking Twist For Its Huntington's DrugInvestors Business Daily • 09/29/26
UniQure's Huntington's therapy fails to significantly slow disease progression in trialReuters • 09/29/26
uniQure Announces Additional Data from Ongoing Phase I/II Studies of ifezuntirgene inilparvovec (AMT-130) in Huntington's Disease Showing Continued Slowing of Disease ProgressionGlobeNewsWire • 09/29/26
QURE Submits Application for Gene Therapy for Huntington's DiseaseZacks Investment Research • 09/03/26
uniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's DiseaseGlobeNewsWire • 09/02/26
QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/YZacks Investment Research • 07/30/26
uniQure Announces Second Quarter 2026 Financial Results and Provides Company UpdateGlobeNewsWire • 07/29/26
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond HemgenixZacks Investment Research • 07/17/26
Is QURE Stock Attractive After Its Rally, Rich Valuation, and Hold?Zacks Investment Research • 07/17/26
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional SharesGlobeNewsWire • 06/25/26